Table 1.
Main Ongoing Clinical Trials of anti- LAG-3 Combined with anti-PD-1 antibody.
| NO. | NCT Number | Title | Tumor | Interventions | Phases |
|---|---|---|---|---|---|
| 1 | NCT02658981 | A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM | GBM | LAG-3 Antibody; PD-1 Antibody | Phase 1 |
| 2 | NCT03250832 | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors | Solid Tumors | TSR-033;Dostarlimab;mFOLFOX6;FOLFIRI;Bevacizumab | Phase 1 |
| 3 | NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | HNSCC | Nivolumab;Relatlimab;Ipilimumab | Phase 2 |
| 4 | NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Solid Tumors | RO7247669 | Phase 1 |
| 5 | NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Solid Tumors | Relatlimab;Nivolumab;BMS-986213 | Phase 1/2 |
| 6 | NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Melanoma | INCAGN02385;INCAGN02390;INCMGA00012 | Phase 1/2 |
| 7 | NCT02061761 | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | HematologicNeoplasms | BMS-986016;BMS-936558 | Phase 1/2 |
| 8 | NCT03005782 | Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers | Solid Tumors | REGN3767;cemiplimab | Phase 1 |
| 9 | NCT03311412 | Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Tumor | Sym021;Sym022;Sym023 | Phase 1 |
| 10 | NCT04641871 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Solid Tumors | Sym021;Sym022;Sym023 | Phase 1 |
| 11 | NCT03743766 | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | Melanoma | Relatlimab;Nivolumab; | Phase 2 |
| 12 | NCT04618393 | A Study of EMB-02 in Participants With Advanced Solid Tumors | Solid Tumors | EMB-02 | Phase 1/2 |
| 13 | NCT04785820 | A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Esophageal Squamous Cell Carcinoma | RO7121661;RO7247669;Nivolumab | Phase 2 |
| 14 | NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Solid Tumors | MGD013;margetuximab | Phase 1 |
| 15 | NCT03623854 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | Chordoma | Nivolumab;Relatlimab | Phase 2 |
| 16 | NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | HNSCC | Enoblituzumab;Retifanlimab;Tebotelimab | Phase 2 |
| 17 | NCT02966548 | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | Solid Tumors | Relatlimab;Nivolumab | Phase 1 |
| 18 | NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | Solid Tumors | Relatlimab;Nivolumab;BMS-986205;Ipilimumab | Phase 1/2 |
| 19 | NCT03044613 | Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | Esophageal Cancer | Nivolumab;Relatlimab;Carboplatin;Paclitaxel;Radiation: Radiation | Phase 1 |
| 20 | NCT04326257 | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | HNSCC | Nivolumab+Relatlimab;Nivolumab+Ipilimumab | Phase 2 |
| 21 | NCT04913922 | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | Acute Myeloid Leukemia | Azacitidine Injection;Nivolumab;Relatlimab | Phase 2 |
| 22 | NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Solid and Hematologic Malignancies | PDR001;LAG525 | Phase 2 |
| 23 | NCT03642067 | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | Colorectal Adenocarcinoma | Nivolumab;Relatlimab | Phase 2 |
| 24 | NCT03607890 | Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Solid Tumors | Nivolumab;Relatlimab | Phase 2 |
| 25 | NCT04658147 | Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | Nivolumab;Relatlimab | Phase 1 |
Abbreviations: Relatlimab, anti-LAG3 antibody; RO7247669, an anti PD-1 and LAG-3 bispecific antibody; BMS-986016, anti-LAG-3; BMS-936558, anti-PD-1 Monoclonal Antibody (Nivolumab); EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3; RO7121661, a PD1-TIM3 Bispecific Antibody; RO7247669, a PD1-LAG3 Bispecific Antibody; MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3; PDR001, PD-1 IgG4 antibody; LAG525, LAG-3 antibody; HNSCC, Head and Neck Squamous Cell Carcinoma; GBM, Glioblastoma.